Vaccines for covid-19 patients

As part of the COVID-NMA initiative, we are identifying all randomized controlled trials (RCTs) of COVID-19 vaccine.

Below, you can access

Of note: For risk of bias assessment, we are considering the “effect of assignment to intervention” which might not be the analysis planned and reported by investigators. Consequently, when investigators planned to assess and report the “per-protocol” effect, the risk of bias for domain 2 may be evaluated as “some concerns”. We will contact investigators to obtain the results of the intent-to-treat analysis.

Treatment comparisons

We report below the forest plots for the main treatment comparisons.

Please choose a Treatment Comparison:

Last update: 22/01/2021

Trial Type Comparisons Design Participants Sample size Overall risk
of bias
Full description
Intervention 1 Intervention 2
NCT04324606; ISRCTN15281137; EudraCT 2020-001072-15
University of Oxford/AstraZeneca
Folegatti PM (COV001), Lancet, 2020

Full text

Barrett JR, Nature medicine, 2020
Full text

Ewer KJ, Nature medicine, 2020
Full text

Commentary
Commentary
Non replicating viral vector ChAdOx1 MenACWY RCT
Phase 1/2
Healthy adults with no history of laboratory confirmed SARS-CoV-2 infection or of COVID-19-like symptoms in five centres in the UK N=1077
Low
Details

Full description

NCT04368988
Novavax
Keech C., N Engl J Med, 2020
Full text
Commentary
Non replicating viral vector 2 dose 25mcg NVX-D0/21 Placebo RCT
Phase 1
Healthy adult volunteers, SARS-CoV-2 infection-free and no history of SARS-CoV-2 infection in two centres in Australia. N=134
Some concerns
Details

Full description

2 dose 5mcg NVX/M1-D0/21 Placebo
2 dose 25mcg NVX/M1-D0/21 Placebo
1 dose 25mcg NVX/M1+Placebo-D0/21 Placebo
NCT04436276
Janssen Pharmaceutical Companies
Sadoff J,MedRxiv,2020
Full text
Commentary
Non replicating viral vector Ad26.COV2.S 5x10^10vp Placebo RCT
Phase 1
Healthy SARS-CoV-2 nucleic acid negative adults 18-55 years old and elderly >65 years old in multiple centres in Belgium and the US N=785
High
Details

Full description

Ad26.COV2.S 1x10^11vp Placebo
NCT04400838
University of Oxford/AstraZeneca
Voysey M (COV002), Lancet, 2020
Full text
Commentary
Non replicating viral vector ChAdOx1 LD/SD 1/2 doses MenACWY RCT
Phase 2/3
Healthy adults in 18 centers in the UK N=7548
Some concerns
Details

Full description

ChAdOx1 SD/SD 1/2 doses MenACWY
ISRCTN89951424
University of Oxford/AstraZeneca
Voysey M (COV003), Lancet, 2020

Full text
Commentary
Non replicating viral vector ChAdOx1 SD/SD MenACWY/saline RCT
Phase 3
Healthy SARS-CoV-2 serology/DNA negative adults in six centres in Brazil N=4088
Some concerns
Details

Full description

NCT04444674
University of Oxford/AstraZeneca
Voysey M (COV005), Lancet, 2020

Full text
Commentary
Non replicating viral vector ChAdOx1 std 2 doses Saline RCT
Phase 1/2
Healthy adults from four studies in multiple centres in Brazil, South Africa, and the UK N=2013

Details

Full description

NCT04341389
CanSino Biological Inc./Beijing Institute of Biotechnology
Zhu F, The Lancet, 2020
Full text
Commentary
Commentary
Non replicating viral vector Adenovirus type-5-vectored COVID-19 1 × 10¹¹ vp Placebo RCT
Phase 2
Healthy adult volunteers with HIV-negative and SARS-CoV-2 infection-free in a single centre in China. N=508
Some concerns
Details

Full description

Adenovirus type-5-vectored COVID-19 5×10¹° vp Placebo
Adenovirus type-5-vectored COVID-19 1 × 10¹¹ vp Adenovirus type-5-vectored COVID-19 5×10¹° vp

The link in the column "Overall risk of bias" provides access to a complete description of the assessment of each risk of bias domain with supports for judgement produced using the Revised Cochrane risk-of-bias tool for randomized trials RoB 2.

The overall risk of bias reported in the table corresponds to the highest risk of bias for the outcomes assessed for the systematic review. The link in the column "Full description" provides access to the general characteristics of the study.

We acknowledge that we may have been unable to extract some information from pre-prints, as they represent preliminary forms of scientific communication.